Format

Send to

Choose Destination
Asian Pac J Cancer Prev. 2014;15(12):5019-22.

Lack of CHEK2 gene mutations in differentiated thyroid carcinoma patients using high resolution melting analysis.

Author information

1
Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran E-mail : fard-esfahani@pasteur.ac.ir.

Abstract

Recently, mutations in the genes involved in cell cycle control, including CHEK2, are being considered as etiological factors in different kinds of cancers. The CHEK2 protein plays an important role in protecting damaged DNA from entering mitosis. In this study the potential effects of two common mutations IVS2+1G?A and Ile157Thr of CHEK2 gene in differentiated thyroid carcinoma (DTC) were evaluated. A total of 100 patients admitted to the Research Institute for Nuclear Medicine were diagnosed with DTC based on pathology reports of surgery samples. An additional 100 people were selected as a control group with no cancer history. PCR-HRM (high resolution melting) analysis was performed to deal with each of mutations in all case and control samples separately. During the analysis of IVS2+1G?A and Ile157Thr mutations of CHEK2 gene in the case and control groups, all the samples were identified as wild homozygote type. The finding suggests that IVS2+1G?A and Ile157Thr mutations of CHEK2 gene do not constitute a risk factor for DTC in the Iranian population. However, further studies with a larger population are required to confirm the outcome.

PMID:
24998580
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Asian Pacific Organization for Cancer Prevention
Loading ...
Support Center